Clinical issues surrounding once-daily aminoglycoside dosing in children

Pharmacotherapy

Volumn 23, Issue 1, 2003, Pages 44-56

  Knoderer, Chad A ^a   Everett, Julie A ^b   Buss, William F ^a  

^a RILEY HOSPITAL FOR CHILDREN   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CEFTAZIDIME; CEFTRIAXONE; GENTAMICIN; METRONIDAZOLE; PIPERACILLIN; TOBRAMYCIN;

CHILD; CHILDHOOD DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESISTANCE; DRUG SAFETY; FEBRILE NEUTROPENIA; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OTOTOXICITY; POSTANTIBIOTIC EFFECT; REVIEW; URINARY TRACT INFECTION;

EID: 0037226805     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.1.44.31924     Document Type: Review

References (57)

1. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:786-95.
2. Barza M, loannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312:338-45.
3. Freeman CD, Nicolau DP, Belliveau PP, et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997;39:677-86.
4. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 1997;24:810-15.
5. Hollender LF, Bahnini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother 1989;23:773-83.
6. Marik PE, Lipman J, Kobilski S, et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and pediatric patients. J Antimicrob Chemother 1991;28:753-64.
7. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996;37:645-63.
8. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered in 2, 184 adult patients. Antimicrob Agents Chemother 1995;39:650-5.
9. Nordstrom L, Ringberg H, Cronberg S, et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990;25:159-73.
10. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9.
11. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.
12. Sturm AW. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989;159(5):931-7.
13. Rozdzinski E, Kern WV, Moritz T, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993;31:585-98.
14. Chuck SK, Raber SR, Rodvold KA. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 2000;30:433-9.
15. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc 1999;74(5):519-28.
16. Lacy MK, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998;27:23-7.
17. Levison ME. Pharmacodynamics of antibacterial drugs. Infect Dis Clin North Am 2000;14(2):281-91.
18. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149(3):443-8.
19. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984;77:657-62.
20. Noonce P, Parsons TMC, Pattison JR, et al. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974;1:477-81.
21. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155(1):93-9.
22. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
23. Daikos GL, Jackson GG, Lolans VT, et al. Adaptive resistance to aminoglycoside antibiotics from first-exposure downregulation. J Infect Dis 1990;162:414-20.
24. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991;35:117-23.
25. Jackson GG, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990;162:408-13.
26. MacArthur RF, Lolans VT, Zar FA, et al. Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis 1984;150:778-9.
27. Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook, 8th ed. Hudson, OH: Lexi-Comp, 2001.
28. MacKenzie FM, Gould IM. The postantibiotic effect. J Antimicrob Chemother 1993;32:519-37.
29. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985;15(suppl A):37-46.
30. Fantin B, Ebert S, Leggett J, et al. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother 1990;27:829-36.
31. Vogelman B, Gudmundsson S, Turnidge J. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988;157(2):287-98.
32. Van der Auwera P, Klastersky J. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin. Antimicrob Agents Chemother 1987;31(7):1061-8.
33. Mingeot-Leclercq MP, Tulkens P. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999; 43(5):1003-12.
34. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45(1):22-7.
35. Giuliano RA, Verpooten GA, Verbist L. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986;236:470-5.
36. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991;27(suppl C):41-7.
37. Bertino JS, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993;167:173-9.
38. Rybak MJ, Abate BJ, Kang L, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999;43(7):1549-55.
39. Murry KR, McKinnon PS, Mitrzyk B, et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999;19(11):1252-60.
40. Black FO, Pesznecker SC. Vestibular ototoxicity: clinical considerations. Otolaryngol Clin North Am 1993;26(5):713-36.
41. Matz GJ. Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am 1993;26(5):705-12.
42. Govaerts PJ, Claes J, Van De Heyning PH, et al. Amino-glycoside-induced ototoxicity. Toxicol Lett 1990;52(3):227-51.
43. Gatell JM, Ferran F, Araujo V, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 1987;31:1383-7.
44. Carapetis JR, Jaquiery AL, Buttery JP, et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatr Infect Dis J 2001;20:240-6.
45. Elhanan K, Siplovich L, Raz R. Gentamicin once-daily versus thrice daily in children. J Antimicrob Chemother 1995;35:327-32.
46. Krivoy N, Postovsky S, Elhasid R, et al. Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients. Infection 1998; 26:396-8.
47. Postovsky S, Ben Arush MW, Kassis E, et al. Pharmacokinetic analysis of gentamicin thrice and single daily dosage in pediatric cancer patients. Pediatr Hematol Oncol 1997;14:547-54.
48. Vic P, Ategbo S, Turck D, et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for Pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 1998;78:536-9.
49. Tomlinson RJ, Rohghe M, Goodbourne C, et al. Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. Arch Dis Child 1999;80:125-31.
50. Bouffet E, Fuhrmann C, Frappaz D, et al. Once daily antibiotic regimen in paediatric oncology. Arch Dis Child 1994;70:484-7.
51. Trujillo H, Robledo J, Robledo C, et al. Single daily dose amikacin in paediatric patients with severe gram-negative infections. J Antimicrob Chemother 1991;27(suppl C):141-7.
52. Kafetzis DA, Sianidou L, Vlachos E, et al. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections. J Antimicrob Chemother 1991;27(suppl C):105-12.
53. Viscoli C, Dudley M, Ferrea G, et al. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 1991;27(suppl C):113-20.
54. Bass KD, Larkin SE, Paap C, et al. Pharmacokinetics of once-daily gentamicin dosing in pediatric patients. J Pediatr Surg 1998;33:1104-7.
55. Bragonier R, Brown NM. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. J Antimicrob Chemother 1998;42:103-6.
56. Shankar SM, Jew RK, Bickert BM, et al. Pharmacokinetics of single daily dose gentamicin in children with cancer. J Pediatr Hematol Oncol 1999;21(4):284-8.
57. Hitt CM, Klepser ME, Nightingale CH, et al. Pharmaco-economic impact of once-daily aminoglycoside administration. Pharmacotherapy 1997;17(4):810-14.